Aktuellt
SENASTE
Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is progressing with a steady OPEX base in line with our expectations. The next stage is the DMC feedback based on the first three patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic breast cancer. This could open up to include patients with additional tumour types during the rest of the phase 1 stage.
LÄS MER
